About: COVID-19 and emerging viral infections: The case for interferon lambda

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: COVID-19 and emerging viral infections: The case for interferon lambda Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	COVID-19 and emerging viral infections: The case for interferon lambda
Creator	Zanoni, Ivan Hartmann, Rune Odendall, Charlotte Prokunina-Olsson, Ludmila Wack, Andreas Kotenko, Sergei Lazear, Helen Onabajo, Olusegun Reich, Nancy Santer, Deanna Durbin, Joan O'brien, Thomas Dickenson, Ruth Alphonse, Noémie Glenn, Jeffrey Piontkivska, Helen
source	Medline; PMC
abstract	With the first reports on coronavirus disease 2019 (COVID-19), which is caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the scientific community working in the field of type III IFNs (IFN-λ) realized that this class of IFNs could play an important role in this and other emerging viral infections. In this Viewpoint, we present our opinion on the benefits and potential limitations of using IFN-λ to prevent, limit, and treat these dangerous viral infections.
has issue date	2020-04-14(xsd:dateTime)
bibo:doi	10.1084/jem.20200653
bibo:pmid	32289152
has license	cc-by-nc-sa
sha1sum (hex)	fd2a2d8f059d6eb55713d2c60a07c6ba3f030a20
schema:url	https://doi.org/10.1084/jem.20200653
resource representing a document's title	COVID-19 and emerging viral infections: The case for interferon lambda
has PubMed Central identifier	PMC7155807
has PubMed identifier	32289152
schema:publication	J Exp Med
resource representing a document's body	covid:fd2a2d8f059d6eb55713d2c60a07c6ba3f030a20#body_text
is schema:about of	named entity 'adverse effects' named entity 'IFNAR2' named entity 'COVID' named entity 'IFN-λ' named entity 'Phase II study' named entity 'MERS-CoV' named entity 'antiproliferative' named entity 'receptor' named entity 'IFN' named entity 'epithelial surfaces' named entity 'tissue damage' named entity 'bacterial infection' named entity 'infection' named entity 'IFN' named entity 'heterodimeric' named entity 'antiviral' named entity 'SARS-CoV-2' named entity 'IFN-λ' named entity 'infection' named entity 'antiviral' named entity 'adverse effects' named entity 'World Health Organization' named entity 'IFN-λ' named entity 'immune cells' named entity 'IFNAR' named entity 'ISGs' named entity 'IFN-λ' named entity 'IL10R2' named entity 'pro-inflammatory' named entity 'type I IFNs' named entity 'IFNα' named entity 'IFNLR1' named entity 'type I IFN' named entity 'IL10R2' named entity 'endothelial cells' named entity 'host-directed' named entity 'IFNLR1' named entity 'prophylactic' named entity 'human disease' named entity 'neutrophil' named entity 'IFNAR' named entity 'tissue damage' named entity 'virus' named entity 'Clinical trials' named entity 'IFN-λ' named entity 'cytokine storm' named entity 'IFN' named entity 'COVID' named entity 'inflammatory responses' named entity 'mice' named entity 'IFNAR' named entity 'animal studies' named entity 'receptor' named entity 'immune response' named entity 'viral infection' named entity 'asymptomatic' named entity 'IFN-λ' named entity 'Infection' named entity 'IFNLR1' named entity 'superinfection' named entity 'IFN-λ' named entity 'prophylaxis' named entity 'type I IFNs' named entity 'type I IFNs' named entity 'IFN-λ' named entity 'viruses'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software